We developed a LANAC-based vaccine containing multiple alphavirus E1 antigens.
The LANAC-based vaccine did not diminish antibody responses to each E1 antigen.
LANAC VEEV E1+WEEV E1 vaccination protected mice against NWAs.
Passive transfer of VEEV E1+WEEV E1 immune sera conferred protection to NWAs.